Cyprotex (AIM :CRX), the drug discovery technology and information company releases preliminary results for the year ended 31 December 2006. Financial highlights included revenues up 30% to £3.5 million, gross profits up 30% to £3 million and basic loss per share narrowed to 0.48p (2005: loss 0.78p).
“2007 started with great optimism. In meeting demands of its customer base, Cyprotex is now able to measure the global opportunity facing it. Management now expects to report a positive income for 2007” said Robert Morrisson Atwater, Chairman.
Shares in Cyprotex firmed after the in-line results and positive outlook for 2007.